Natalie Mount

Dr. Mount brings over 20 years of experience in drug development, including most recently, 8 years of experience specialising in the development of cell and gene therapies. Natalie joined GammaDelta in 2017 from the Cell and Gene Therapy Catapult where she was Chief Clinical Officer since 2012, having been recruited to build the Catapult from the startup phase. At the Catapult, Natalie was responsible for the translational, regulatory and clinical development activities across the broad portfolio including immune therapies and stem cell based programs.

She also acted as an advisor to academics and small companies developing cell based therapies. Natalie’s prior experience also includes 16 years at Pfizer, leading development activities across various therapeutic areas, including cell based therapies in the Regenerative Medicine Unit. Natalie has a first class degree in Natural Sciences from the University of Cambridge and a PhD from University College, London.